By Mr Bradley Roberts, Perron Institute & UWA, and Professor Sean Hood, Perron Institute, UWA and SCGH
Researchers at the Perron Institute for Neurological and Translational Science have recently launched the GENE-YD study, an innovative trial exploring the benefits of pharmacogenetic testing to optimise antidepressant pharmacotherapy in young Western Australians.
This pilot randomised controlled trial aims to explore the feasibility for a larger trial in WA to improve treatment outcomes through personalising patients’ antidepressant prescriptions, helping young people achieve symptom relief faster with fewer medication-related side effects.
Major Depressive Disorder (MDD) is among the leading causes...
Researchers at the Perron Institute for Neurological and Translational Science have recently launched the GENE-YD study, an innovative trial exploring the benefits of pharmacogenetic testing to optimise antidepressant pharmacotherapy in young Western Australians.
This pilot randomised controlled trial aims to explore the feasibility for a larger trial in WA to improve treatment outcomes through personalising patients’ antidepressant prescriptions, helping young people achieve symptom relief faster with fewer medication-related side effects.
Major Depressive Disorder (MDD) is among the leading causes...
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.